雜志介紹

Ejnmmi Research雜志介紹

《Ejnmmi Research》是一本以English為主的開放獲取國際優(yōu)秀期刊，中文名稱恩米研究，本刊主要出版、報道醫(yī)學(xué)-RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING領(lǐng)域的研究動態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進(jìn)展，探討行業(yè)發(fā)展的思路和方法，以促進(jìn)學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動作用，也得到了本專業(yè)人員的廣泛認(rèn)可。該刊最新影響因子為3.1，最新CiteScore 指數(shù)為5.9。

本刊近期中國學(xué)者發(fā)表的論文主要有：

• CMR validation of left ventricular volumes and ejection fraction measured by the IQ-SPECT system in patients with small heart size

  Author: Wei, Hua; Wu, Jiaojiao; Han, Ke; Hu, Guang; Wang, Hongliang; Guo, Xiaoshan; Liu, Haiyan; Wu, Zhifang; Li, Sijin

• Predicting PD-L1 expression status in patients with non-small cell lung cancer using [F-18]FDG PET/CT radiomics

  Author: Zhao, Xiaoqian; Zhao, Yan; Zhang, Jingmian; Zhang, Zhaoqi; Liu, Lihua; Zhao, Xinming

• Direct reconstruction for simultaneous dual-tracer PET imaging based on multi-task learning

  Author: Zeng, Fuzhen; Fang, Jingwan; Muhashi, Amanjule; Liu, Huafeng

• The potential application of MR-derived ADCmin values from Ga-68-DOTATATE and F-18-FDG dual tracer PET/MR as replacements for FDG PET in assessment of grade and stage of pancreatic neuroendocrine tumors

  Author: Gao, Jing; Xu, Si; Ju, Huijun; Pan, Yu; Zhang, Yifan

英文介紹

Ejnmmi Research雜志英文介紹

EJNMMI Research publishes new basic, translational and clinical research in the field of nuclear medicine and molecular imaging. Regular features include original research articles, rapid communication of preliminary data on innovative research, interesting case reports, editorials, and letters to the editor. Educational articles on basic sciences, fundamental aspects and controversy related to pre-clinical and clinical research or ethical aspects of research are also welcome. Timely reviews provide updates on current applications, issues in imaging research and translational aspects of nuclear medicine and molecular imaging technologies.

The main emphasis is placed on the development of targeted imaging with radiopharmaceuticals within the broader context of molecular probes to enhance understanding and characterisation of the complex biological processes underlying disease and to develop, test and guide new treatment modalities, including radionuclide therapy.